PDSB
PDS Biotechnology CorporationNASDAQHealthcare$0.78+22.90%ClosedMarket Cap: $42.7M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
3.91
P/S
0.00
EV/EBITDA
-171.83
DCF Value
$-111.44
FCF Yield
54822.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-258.4%
ROA
-120.8%
ROIC
156.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $8.13B | $-9.9M | $-0.13 | — |
| FY 2025 | $0.00 | NaN% | $-31.54B | $-36.8M | $-0.74 | — |
| Q3 2025 | $0.00 | NaN% | $-8.1M | $-9.0M | $-0.19 | — |
| Q2 2025 | $0.00 | NaN% | $-7.6M | $-9.4M | $-0.21 | — |
| Q1 2025 | $0.00 | NaN% | $-9.1M | $-8.5M | $-0.21 | — |
| Q4 2024 | $0.00 | -Infinity% | $-7.4M | $-8.0M | $-0.22 | — |
| FY 2024 | $0.00 | -Infinity% | $-36.3M | $-37.6M | $-1.03 | — |
| Q3 2024 | $0.00 | NaN% | $-10.2M | $-10.7M | $-0.29 | — |
| Q2 2024 | $0.00 | NaN% | $-8.7M | $-8.3M | $-0.23 | — |
| Q1 2024 | $0.00 | NaN% | $-10.1M | $-10.6M | $-0.30 | — |
| Q4 2023 | $0.00 | NaN% | $-10.4M | $-10.9M | $-0.34 | — |
| FY 2023 | $0.00 | -Infinity% | $-43.0M | $-42.9M | $-1.39 | — |